Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Spindle Epithelial Tumor With Thymus-Like Differentiation in an Infant.

Pediatrics·2026
Same author

Paediatric therapeutic development workshop on medulloblastoma.

British journal of cancer·2026
Same author

Altered development in auditory white matter and cortical response latency in youth with neurofibromatosis type I.

Neuroreport·2026
Same author

Racial disparities in pediatric cancer hospitalizations in the United States.

Cancer epidemiology·2026
Same author

Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children's Oncology Group study ACNS0333.

Neuro-oncology pediatrics·2026
Same author

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Neuro-oncology·2026

相关实验视频

Updated: Jan 17, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.1K

在IDH突变高度质瘤中.

Santosh Valvi1,2,3, Maryam Fouladi4, Michael J Fisher5,6

  • 1Department of Pediatric and Adolescent Oncology and Hematology, Perth Children's Hospital, Perth, WA, Australia.

Frontiers in molecular neuroscience
|September 15, 2025
PubMed
概括

异酸脱酶 (IDH) 突变定义了一个独特的质瘤子类,具有更好的结果. 本综述涵盖了儿童和年轻人的IDH突变质瘤,重点是生物学,诊断,治疗和预后.

关键词:
IDH 抑制剂的使用发生IDH突变的IDH突变.青少年和年轻人的成年人.临床试验是指临床试验中的临床试验.高度质瘤高度质瘤儿科 儿科 儿科

更多相关视频

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.4K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.5K

相关实验视频

Last Updated: Jan 17, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.1K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.4K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.5K

科学领域:

  • 神经瘤学神经瘤学
  • 分子病理学分子病理学
  • 癌症遗传学 癌症遗传学

背景情况:

  • 质瘤是主要的中枢神经系统 (CNS) 瘤,患病率和死亡率高,特别是在儿科和青少年和年轻成人 (AYA) 群体中.
  • 异酸脱酶 (IDH) 基因突变是质瘤分类的关键驱动因素,区分具有独特临床和分子形状的瘤.
  • 虽然IDH突变在成年人中更为普遍,但在5-15%的儿科质瘤中发现,影响预后和治疗反应.

研究的目的:

  • 提供关于IDH突变高度质瘤 (HGG) 的当前知识的全面审查.
  • 总结一下IDH突变质瘤的生物学,临床特征,诊断,治疗和预后.
  • 突出未来的研究和临床管理策略,重点关注AYA队列.

主要方法:

  • 关于IDH突变质瘤的文献综述.
  • 综合有关分子特征,临床表现和治疗结果的数据.
  • 对预后因素和未来研究方向的分析.

主要成果:

  • 与IDH-野生型质瘤相比,IDH突变质瘤表现出明显的生物学和临床特征.
  • 这些瘤通常显示出更有利的预后和更好的治疗反应.
  • 该审查巩固了IDH突变HGG的各个方面目前的理解.

结论:

  • IDH突变状态是结质瘤分类和患者结局的关键决定因素.
  • 了解IDH突变质瘤对于推进治疗策略至关重要,特别是在儿科和AYA患者中.
  • 需要进一步的研究来优化管理和改善这种特定的质瘤亚型的存活率.